Skip to main content
SpringerLink
Log in

The Three-Decade Long Journey in Heart Failure Drug Development

  • Chapter
  • First Online:
Book cover Heart Failure

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 243))

Abstract

Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This paper will briefly summarize the burden of disease, HF classification and definitions and the landmark clinical trials in both HFrEF and HFpEF. Given the increasing incidence and prevalence of HF and the high morbidity and mortality associated with this disease, continued development efforts are essential to address the unmet needs of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams KF Jr, Fonarow GC, Emerman CL et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209–216

    Article  PubMed  Google Scholar 

  • Ambrosy AP, Fonarow GC, Butler J et al (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123–1133

    Article  PubMed  Google Scholar 

  • Bauersachs J, Jaisser F, Toto R (2015) Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65(2):257–263

    Article  CAS  PubMed  Google Scholar 

  • Blecker S, Paul M, Taksler G et al (2013) Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 61(12):1259–1267

    Article  PubMed  Google Scholar 

  • Bohm M, Perez AC, Jhund PS et al (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 16(7):778–787

    Article  PubMed  Google Scholar 

  • Braunwald E (2013) Heart failure. JACC Heart Fail 1(1):1–20

    Article  PubMed  Google Scholar 

  • Brenner H, Bouvier AM, Foschi R et al (2012) Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer 131(7):1649–1658

    Article  CAS  PubMed  Google Scholar 

  • Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8(1):30–41

    Article  PubMed  Google Scholar 

  • Capomolla S, Febo O, Gnemmi M et al (2000) Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 139(4):596–608

    Article  CAS  PubMed  Google Scholar 

  • Carson P, Ziesche S, Johnson G et al (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-heart failure trial study group. J Card Fail 5(3):178–187

    Article  CAS  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention (2016) Available at http://www.cdc.gov/nchs/ahcd. Accessed 17 June 2016

  • Cleland JG, Dargie HJ, Ball SG et al (1985) Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. British Heart J 54(3):305–312

    Article  CAS  Google Scholar 

  • Cleland JG, Tendera M, Adamus J et al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–1675

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Archibald DG, Ziesche S et al (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med 314(24):1547–1552

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Johnson G, Ziesche S et al (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325(5):303–310

    Article  CAS  PubMed  Google Scholar 

  • Cole RT, Kalogeropoulos AP, Georgiopoulou VV et al (2011) Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation 123(21):2414–2422

    Article  PubMed  Google Scholar 

  • Coleman MP, Forman D, Bryant H et al (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. The Lancet 377(9760):127–138

    Article  CAS  Google Scholar 

  • Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933–989

    Article  PubMed  Google Scholar 

  • Digitalis Investigation G (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525–533

    Article  Google Scholar 

  • Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group (1987). N Engl J Med 316 (23):1429–1435.

    Google Scholar 

  • Erhardt L, MacLean A, Ilgenfritz J et al (1995) Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) study group. Eur Heart J 16(12):1892–1899

    Article  CAS  PubMed  Google Scholar 

  • EudraCT (2012) Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study

    Google Scholar 

  • Filippatos G, Anker SD, Bohm M et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37(27):2105–2114

    Article  PubMed  PubMed Central  Google Scholar 

  • Florea VG, Rector TS, Anand IS et al (2016) Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial. Circ Heart Fail 9(7)

    Google Scholar 

  • Fonarow GC, Stough WG, Abraham WT et al (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 50(8):768–777

    Article  PubMed  Google Scholar 

  • Gheorghiade M, Marti CN, Sabbah HN et al (2013) Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 18(2):123–134

    Article  CAS  PubMed  Google Scholar 

  • Go AS, Mozaffarian D, Roger VL et al (2013) Heart disease and stroke statistics – 2013 update: a report from the American heart association. Circulation 127(1):e6–e245

    Article  PubMed  Google Scholar 

  • Greene SJ, Gheorghiade M, Borlaug BA et al (2013) The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc 2(6):e000536

    Article  PubMed  PubMed Central  Google Scholar 

  • Heidenreich PA, Albert NM, Allen LA et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American heart association. Circ Heart Fail 6(3):606–619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Konstam MA, Neaton JD, Dickstein K et al (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet 374(9704):1840–1848

    Article  CAS  Google Scholar 

  • Lechat P, Hulot JS, Escolano S et al (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 103(10):1428–1433

    Article  CAS  PubMed  Google Scholar 

  • Lloyd-Jones DM, Larson MG, Leip EP et al (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24):3068–3072

    Article  PubMed  Google Scholar 

  • Maggioni AP, Dahlstrom U, Filippatos G et al (2013) EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15(7):808–817

    Article  PubMed  Google Scholar 

  • Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467

    Article  CAS  PubMed  Google Scholar 

  • McKelvie RS, Komajda M, McMurray J et al (2010) Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 16(2):128–134

    Article  CAS  PubMed  Google Scholar 

  • Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93(9):1137–1146

    Article  PubMed  PubMed Central  Google Scholar 

  • 1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325(5):293–302

    Google Scholar 

  • Packer M (2016) Heart failure’s dark secret: does anyone really care about optimal medical therapy? Circulation 134(9):629–631

    Article  PubMed  Google Scholar 

  • Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17):2194–2199

    Article  PubMed  Google Scholar 

  • Packer M, Desai AS, Gong J et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004

    Article  PubMed  Google Scholar 

  • Packer M, McMurray JJ, Desai AS et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54–61

    Article  CAS  PubMed  Google Scholar 

  • Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271

    Article  PubMed  Google Scholar 

  • Pfeffer MA, Braunwald E, Moye LA et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10):669–677

    Article  CAS  PubMed  Google Scholar 

  • Pfeffer MA, McMurray JJV, Velazquez EJ et al (2003a) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349(20):1893–1906

    Article  CAS  PubMed  Google Scholar 

  • Pfeffer MA, Swedberg K, Granger CB et al (2003b) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362(9386):759–766

    Article  CAS  PubMed  Google Scholar 

  • Pfeffer MA, Claggett B, Assmann SF et al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 131(1):34–42

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341(10):709–717

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Williams G, Remme W et al (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther/sponsored by the Int Soc Cardiovasc Pharmacother 15(1):79–87

    Article  CAS  Google Scholar 

  • Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392

    Article  CAS  PubMed  Google Scholar 

  • Pocock SJ, Wang D, Pfeffer MA et al (2006) Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27(1):65–75

    Article  PubMed  Google Scholar 

  • Ponikowski P, Anker SD, AlHabib KF et al (2014) Heart failure: preventing disease and death worldwide. ESC Heart Fail 1:4–25, http://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf

    Article  Google Scholar 

  • Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200

    Article  PubMed  Google Scholar 

  • Poole-Wilson PA, Swedberg K, Cleland JG et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 362(9377):7–13

    Article  CAS  PubMed  Google Scholar 

  • Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. Jama 309(12):1268–1277

    Article  CAS  PubMed  Google Scholar 

  • Redfield MM, Anstrom KJ, Levine JA et al (2015) Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 373(24):2314–2324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sakata Y, Shimokawa H (2013) Epidemiology of heart failure in Asia. Circ J official J Japn Circ Soc 77(9):2209–2217

    Google Scholar 

  • Sanderson JE (2007) Heart failure with a normal ejection fraction. Heart 93(2):155–158

    Article  CAS  PubMed  Google Scholar 

  • Sasayama S (2008) Heart disease in Asia. Circulation 118(25):2669–2671

    Article  PubMed  Google Scholar 

  • Sharpe DN, Murphy J, Coxon R et al (1984) Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70(2):271–278

    Article  CAS  PubMed  Google Scholar 

  • Shiba N, Shimokawa H (2008) Chronic heart failure in Japan: implications of the CHART studies. Vasc Health Risk manag 4(1):103–113

    Article  PubMed  PubMed Central  Google Scholar 

  • Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241

    Article  PubMed  Google Scholar 

  • Swedberg K, Komajda M, Bohm M et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine trial) study. J Am Coll Cardiol 59(22):1938–1945

    Article  CAS  PubMed  Google Scholar 

  • Taylor AL, Ziesche S, Yancy C et al (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351(20):2049–2057

    Article  CAS  PubMed  Google Scholar 

  • Vaduganathan M, Michel A, Hall K et al (2016) Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 18(1):54–65

    Article  PubMed  Google Scholar 

  • van Veldhuisen DJ, Cohen-Solal A, Bohm M et al (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53(23):2150–2158

    Article  PubMed  Google Scholar 

  • Writing Committee M, Yancy CW, Jessup M et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240–e327

    Article  Google Scholar 

  • Writing Group M, Mozaffarian D, EJ B et al (2016) Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation 133(4):e38–360

    Article  Google Scholar 

  • Yancy CW, Lopatin M, Stevenson LW et al (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47(1):76–84

    Article  PubMed  Google Scholar 

  • Yancy CW, Jessup M, Bozkurt B et al. (2016) 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for Heart Failure: an update of the 2013 ACCF/AHA guideline for the management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation

    Google Scholar 

  • Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362(9386):777–781

    Article  CAS  PubMed  Google Scholar 

  • Zannad F, Agrinier N, Alla F (2009) Heart failure burden and therapy. Europace 11(Suppl 5):v1–v9

    Article  PubMed  Google Scholar 

  • Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21

    Article  CAS  PubMed  Google Scholar 

  • Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Global Medical Affairs, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA

    Kelly S. Lewis

  2. Department of Medicine, Division of Cardiovascular Medicine, Stony Brook University, Stony Brook, NY, USA

    Javed Butler

  3. Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

    Johann Bauersachs

  4. Department of Cardiology, Global Drug Discovery, Bayer Pharma AG, Wuppertal, Germany

    Peter Sandner

Authors
  1. Kelly S. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johann Bauersachs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Sandner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly S. Lewis .

Editor information

Editors and Affiliations

  1. Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover Klinik für Kardiologie und Angiologie, Hannover, Niedersachsen, Germany

    Johann Bauersachs

  2. Heart Institute, Stony Brook University , Stony Brook, New York, USA

    Javed Butler

  3. Heart and Lung Diseases, Bayer Pharma Aktiengesellschaft Heart and Lung Diseases, Wuppertal, Nordrhein-Westfalen, Germany

    Peter Sandner

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lewis, K.S., Butler, J., Bauersachs, J., Sandner, P. (2016). The Three-Decade Long Journey in Heart Failure Drug Development. In: Bauersachs, J., Butler, J., Sandner, P. (eds) Heart Failure. Handbook of Experimental Pharmacology, vol 243. Springer, Cham. https://doi.org/10.1007/164_2016_101

Download citation

Publish with us

Policies and ethics

Search

Navigation